Trenson Sander, Kahr Peter C, Vandenberk Bert, Schindler Matthias, Breitenstein Alexander, Saguner Ardan M, Flammer Andreas J, Ruschitzka Frank, Duru Firat, Steffel Jan, Winnik Stephan H
University Heart Center, University Hospital Zurich, Zurich, Switzerland; Cardiovascular Sciences, University Hospital Leuven, Leuven, Belgium; Department of Cardiovascular Sciences, University Hospital Leuven, Leuven, Belgium.
University Heart Center, University Hospital Zurich, Zurich, Switzerland.
JACC Adv. 2025 Jul 26;4(8):101909. doi: 10.1016/j.jacadv.2025.101909.
Cardiac resynchronization therapy (CRT) reduces morbidity and mortality in selected heart failure patients. A distinct subpopulation (so-called "nonprogressors") of patients shows neither amelioration nor worsening of echocardiographic parameters after CRT implantation.
The authors sought to investigate the long-term outcomes and prognosis of a distinct subpopulation of heart failure patients termed "nonprogressors," after CRT implantation.
Retrospective single-center cohort analysis of 391 patients after CRT implantation. Based on echocardiography, patients were categorized into "super-responders" (Δ left ventricular ejection fraction [LVEF] >15% compared to baseline), "responders" (ΔLVEF >5% compared to baseline), "nonprogressors" (ΔLVEF ±5% compared to baseline), and "progressors" (ΔLVEF <-5% compared to baseline). The primary composite outcome was all-cause death, implantation of a ventricular assist device, or heart transplantation. Statistics included univariable and multivariable Cox proportional hazard regression analysis and Kaplan-Meier survival curves to explore outcome data.
Three hundred ninety-one patients (23% female, mean age 65 years, mean baseline LVEF 27%) were included. Postimplantation echocardiograms were performed after a mean of 37 months after CRT implantation. A total of 134 patients (34%) were nonprogressors. After a mean follow-up of another 57 months, progressors were significantly more likely to reach the composite endpoint of death, ventricular assist device implantation, or heart transplantation compared to nonprogressors (adjusted HR: 2.26 [95% CI: 1.35-3.78]; P = 0.002). Patients with positive echocardiographic response and super-response fared significantly better compared to nonprogressors.
Nonprogressors form a relevant, to date poorly characterized group of CRT patients, whose long-term survival is significantly better compared to progressors or negative responders.
心脏再同步治疗(CRT)可降低特定心力衰竭患者的发病率和死亡率。有一部分特殊患者群体(即所谓的“无进展者”)在植入CRT后,其超声心动图参数既未改善也未恶化。
作者试图研究植入CRT后被称为“无进展者”的特殊心力衰竭患者亚群的长期结局和预后。
对391例植入CRT后的患者进行回顾性单中心队列分析。根据超声心动图,患者被分为“超反应者”(与基线相比,左心室射血分数[LVEF]增加>15%)、“反应者”(与基线相比,LVEF增加>5%)、“无进展者”(与基线相比,LVEF变化±5%)和“进展者”(与基线相比,LVEF降低<-5%)。主要复合结局为全因死亡、植入心室辅助装置或心脏移植。统计方法包括单变量和多变量Cox比例风险回归分析以及Kaplan-Meier生存曲线,以探索结局数据。
纳入391例患者(23%为女性,平均年龄65岁,平均基线LVEF为27%)。在CRT植入后平均37个月进行植入后超声心动图检查。共有134例患者(34%)为无进展者。在平均随访另外57个月后,与无进展者相比,进展者达到死亡、心室辅助装置植入或心脏移植复合终点的可能性显著更高(校正后HR:2.26[95%CI:1.35 - 3.78];P = 0.002)。与无进展者相比,超声心动图有阳性反应和超反应的患者预后明显更好。
无进展者是CRT患者中一个相关但迄今特征描述不足的群体,其长期生存率明显高于进展者或无反应者。